{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T04:40:09Z","timestamp":1733719209273,"version":"3.30.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T00:00:00Z","timestamp":1731628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T00:00:00Z","timestamp":1731628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s00520-024-09012-1","type":"journal-article","created":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T23:21:00Z","timestamp":1731626460000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immune-related adverse events in cancer patients referred to the palliative care team of a tertiary care center: a retrospective observational study"],"prefix":"10.1007","volume":"32","author":[{"given":"Ryota","family":"Yanaizumi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Nagamine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinsuke","family":"Harada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahisa","family":"Goto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,15]]},"reference":[{"key":"9012_CR1","doi-asserted-by":"publisher","unstructured":"Benz S, Sherman KA, Dasanu CA, Alvarez-Argote J (2023) Immune checkpoint inhibitor-related adverse events: Real-world experience from a single veterans' affairs medical center. J Oncol Pharm Pract: 10781552231184178. https:\/\/doi.org\/10.1177\/10781552231184178","DOI":"10.1177\/10781552231184178"},{"key":"9012_CR2","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1200\/jco.2012.41.6750","volume":"30","author":"JS Weber","year":"2012","unstructured":"Weber JS, K\u00e4hler KC, Hauschild A (2012) Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 30:2691\u20132697. https:\/\/doi.org\/10.1200\/jco.2012.41.6750","journal-title":"J Clin Oncol"},{"key":"9012_CR3","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1093\/annonc\/mdv182","volume":"26","author":"TW Chen","year":"2015","unstructured":"Chen TW, Razak AR, Bedard PL, Siu LL, Hansen AR (2015) A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors. Ann Oncol 26:1824\u20131829. https:\/\/doi.org\/10.1093\/annonc\/mdv182","journal-title":"Ann Oncol"},{"key":"9012_CR4","doi-asserted-by":"publisher","first-page":"6107","DOI":"10.1007\/s00520-020-05727-z","volume":"28","author":"BL Rapoport","year":"2020","unstructured":"Rapoport BL, Anderson R, Cooksley T, Johnson DB (2020) MASCC 2020 recommendations for the management of immune-related adverse events of patients undergoing treatment with immune checkpoint inhibitors. Support Care Cancer 28:6107\u20136110. https:\/\/doi.org\/10.1007\/s00520-020-05727-z","journal-title":"Support Care Cancer"},{"key":"9012_CR5","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378:158\u2013168. https:\/\/doi.org\/10.1056\/NEJMra1703481","journal-title":"N Engl J Med"},{"key":"9012_CR6","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s00520-021-06482-5","volume":"30","author":"Y Usui","year":"2022","unstructured":"Usui Y, Miura T, Kawaguchi T, Kosugi K, Uehara Y, Kato M, Kosugi T, Sone M, Nakamura N, Mizushima A, Miyashita M, Morita T, Yamaguchi T, Matsumoto Y, Satomi E (2022) Palliative care physicians\u2019 recognition of patients after immune checkpoint inhibitors and immune-related adverse events. Support Care Cancer 30:775\u2013784. https:\/\/doi.org\/10.1007\/s00520-021-06482-5","journal-title":"Support Care Cancer"},{"key":"9012_CR7","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.annemergmed.2018.04.019","volume":"73","author":"I El Majzoub","year":"2019","unstructured":"El Majzoub I, Qdaisat A, Thein KZ, Win MA, Han MM, Jacobson K, Chaftari PS, Prejean M, Reyes-Gibby C, Yeung SJ (2019) Adverse effects of immune checkpoint therapy in cancer patients visiting the emergency department of a comprehensive cancer center. Ann Emerg Med 73:79\u201387. https:\/\/doi.org\/10.1016\/j.annemergmed.2018.04.019","journal-title":"Ann Emerg Med"},{"key":"9012_CR8","unstructured":"(2017) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf Accessed 15 October 2024"},{"key":"9012_CR9","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","volume":"335","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP (2007) Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ 335:806\u2013808. https:\/\/doi.org\/10.1136\/bmj.39335.541782.AD","journal-title":"BMJ"},{"key":"9012_CR10","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s12943-019-1091-2","volume":"18","author":"S Qin","year":"2019","unstructured":"Qin S, Xu L, Yi M, Yu S, Wu K, Luo S (2019) Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol Cancer 18:155. https:\/\/doi.org\/10.1186\/s12943-019-1091-2","journal-title":"Mol Cancer"},{"key":"9012_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002886","author":"L Zubiri","year":"2021","unstructured":"Zubiri L, Molina GE, Mooradian MJ, Cohen J, Durbin SM, Petrillo L, Boland GM, Juric D, Dougan M, Thomas MF, Faje AT, Rengarajan M, Guidon AC, Chen ST, Okin D, Medoff BD, Nasrallah M, Kohler MJ, Schoenfeld SR, Karp-Leaf RS, Sise ME, Neilan TG, Zlotoff DA, Farmer JR, Bardia A, Sullivan RJ, Blum SM, Semenov YR, Villani AC, Reynolds KL (2021) Effect of a multidisciplinary severe immunotherapy complications service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2021-002886","journal-title":"J Immunother Cancer"},{"key":"9012_CR12","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.jpainsymman.2022.02.013","volume":"63","author":"JJ Koldenhof","year":"2022","unstructured":"Koldenhof JJ, van der Baan FH, Verberne EG, Kamphuis AM, Verheijden RJ, Tonk EH, van Lindert AS, van der Stap J, Teunissen SC, Witteveen PO, Suijkerbuijk KP (2022) Patient-reported outcomes during checkpoint inhibition: insight into symptom burden in daily clinical practice. J Pain Symptom Manage 63:997\u20131005. https:\/\/doi.org\/10.1016\/j.jpainsymman.2022.02.013","journal-title":"J Pain Symptom Manage"},{"key":"9012_CR13","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.jpainsymman.2018.05.015","volume":"56","author":"ED Hansen","year":"2018","unstructured":"Hansen ED, Wang X, Case AA, Puzanov I, Smith T (2018) Immune checkpoint inhibitor toxicity review for the palliative care clinician. J Pain Symptom Manage 56:460\u2013472. https:\/\/doi.org\/10.1016\/j.jpainsymman.2018.05.015","journal-title":"J Pain Symptom Manage"},{"key":"9012_CR14","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1093\/annonc\/mdx286","volume":"28","author":"L Khoja","year":"2017","unstructured":"Khoja L, Day D, Wei-Wu Chen T, Siu LL, Hansen AR (2017) Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann Oncol 28:2377\u20132385. https:\/\/doi.org\/10.1093\/annonc\/mdx286","journal-title":"Ann Oncol"},{"key":"9012_CR15","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","volume":"16","author":"F Martins","year":"2019","unstructured":"Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, Shabafrouz K, Ribi C, Cairoli A, Guex-Crosier Y, Kuntzer T, Michielin O, Peters S, Coukos G, Spertini F, Thompson JA, Obeid M (2019) Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol 16:563\u2013580. https:\/\/doi.org\/10.1038\/s41571-019-0218-0","journal-title":"Nat Rev Clin Oncol"},{"issue":"Suppl 1","key":"9012_CR16","first-page":"18","volume":"85","author":"DH Lawson","year":"1994","unstructured":"Lawson DH (1994) Postmarketing surveillance versus clinical trials: which benefits the patient? Cardiology 85(Suppl 1):18\u201323","journal-title":"Cardiology"},{"key":"9012_CR17","doi-asserted-by":"publisher","first-page":"e213","DOI":"10.3346\/jkms.2018.33.e213","volume":"33","author":"HS Kim","year":"2018","unstructured":"Kim HS, Lee S, Kim JH (2018) Real-world evidence versus randomized controlled trial: clinical research based on electronic medical records. J Korean Med Sci 33:e213. https:\/\/doi.org\/10.3346\/jkms.2018.33.e213","journal-title":"J Korean Med Sci"},{"key":"9012_CR18","doi-asserted-by":"publisher","first-page":"2972","DOI":"10.1093\/annonc\/mdt397","volume":"24","author":"AJ Templeton","year":"2013","unstructured":"Templeton AJ, Vera-Badillo FE, Wang L, Attalla M, De Gouveia P, Leibowitz-Amit R, Knox JJ, Moore M, Sridhar SS, Joshua AM, Pond GR, Amir E, Tannock IF (2013) Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials. Ann Oncol 24:2972\u20132977. https:\/\/doi.org\/10.1093\/annonc\/mdt397","journal-title":"Ann Oncol"},{"key":"9012_CR19","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/jco.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, Atkins MB, Brassil KJ, Caterino JM, Chau I, Davies MJ, Ernstoff MS, Fecher L, Ghosh M, Jaiyesimi I, Mammen JS, Naing A, Nastoupil LJ, Phillips T, Porter LD, Reichner CA, Seigel C, Song JM, Spira A, Suarez-Almazor M, Swami U, Thompson JA, Vikas P, Wang Y, Weber JS, Funchain P, Bollin K (2021) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol 39:4073\u20134126. https:\/\/doi.org\/10.1200\/jco.21.01440","journal-title":"J Clin Oncol"},{"key":"9012_CR20","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/jco.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, Chau I, Ernstoff MS, Gardner JM, Ginex P, Hallmeyer S, HolterChakrabarty J, Leighl NB, Mammen JS, McDermott DF, Naing A, Nastoupil LJ, Phillips T, Porter LD, Puzanov I, Reichner CA, Santomasso BD, Seigel C, Spira A, Suarez-Almazor ME, Wang Y, Weber JS, Wolchok JD, Thompson JA (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. J Clin Oncol 36:1714\u20131768. https:\/\/doi.org\/10.1200\/jco.2017.77.6385","journal-title":"J Clin Oncol"},{"key":"9012_CR21","doi-asserted-by":"publisher","unstructured":"Haanen J, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, Jordan K (2017) Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 28: iv119-iv142. https:\/\/doi.org\/10.1093\/annonc\/mdx225","DOI":"10.1093\/annonc\/mdx225"},{"key":"9012_CR22","doi-asserted-by":"publisher","unstructured":"Strunk A, Batzler YN, Ziemer M, Neukirchen M, Schwartz J, Sachse M, Garzarolli M, Strasser C, Reinhardt L, Kaatz M, Schuler U, Meier F (2023) Raising awareness of immune-related side effects in oncological patients under palliative care: a report of two cases. Ann Palliat Med 12: 826\u2013833. https:\/\/doi.org\/10.21037\/apm-22-1077","DOI":"10.21037\/apm-22-1077"},{"key":"9012_CR23","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s00520-007-0215-1","volume":"16","author":"M Miyashita","year":"2008","unstructured":"Miyashita M, Hirai K, Morita T, Sanjo M, Uchitomi Y (2008) Barriers to referral to inpatient palliative care units in Japan: a qualitative survey with content analysis. Support Care Cancer 16:217\u2013222. https:\/\/doi.org\/10.1007\/s00520-007-0215-1","journal-title":"Support Care Cancer"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-024-09012-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-024-09012-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-024-09012-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T04:16:47Z","timestamp":1733717807000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-024-09012-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,15]]},"references-count":23,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["9012"],"URL":"https:\/\/doi.org\/10.1007\/s00520-024-09012-1","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"type":"print","value":"0941-4355"},{"type":"electronic","value":"1433-7339"}],"subject":[],"published":{"date-parts":[[2024,11,15]]},"assertion":[{"value":"13 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures involving human participants performed in this study were in accordance with the ethical standards of the institutional and\/or national research committee and the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This study was approved by the Ethics Committee of Yokohama City University Medical Center (F220500067; August 4, 2022), Yokohama, Japan. The requirement for written informed consent was waived by the Ethics Committee.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The requirement for written informed consent was waived due to the retrospective nature of this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors consent to publication of this article in Supportive Care in Cancer.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publishing"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"793"}}